How Upright Engineering is Democratizing Proton Therapy in Türkiye

ISTANBUL – September 23, 2026 – For decades, the greatest barrier to advanced cancer care has not been the science of oncology, but the sheer physics of architecture. Traditional proton radiation therapy—long considered the gold standard for treating pediatric and complex tumors—requires accelerating subatomic particles to two-thirds the speed of light. To direct that beam, hospitals have historically relied on massive, 360-degree rotating gantries weighing up to 200 metric tons, housed inside multi-story concrete bunkers with walls three meters thick.

It is a logistical and financial nightmare that has kept life-saving technology out of reach for much of the developing world. But a paradigm shift in medical engineering is finally dismantling that barrier, and its latest proving ground is the crossroads of Europe and Asia.

Mevion Medical Systems recently announced a landmark agreement with Rönesans Holding to bring the MEVION S250-FIT Proton Therapy System™ to Başakşehir Çam ve Sakura City Hospital in Istanbul. The installation, executed in partnership with local distributor Meditel Healthcare, will establish Türkiye’s first domestic proton therapy program. More importantly, it signals a radical reimagining of how advanced radiotherapy is delivered, proving that shrinking the footprint of medical technology is the key to expanding its reach.

The Upright Engineering Revolution

The traditional multi-room proton center is a behemoth, often requiring capital expenditures upwards of $120 million to $200 million. Even single-room gantry systems hover in the $50 million range, demanding extensive greenfield excavation. The MEVION S250-FIT bypasses this entirely by fundamentally flipping the architectural equation: instead of rotating a multi-ton machine around a stationary patient, it rotates the patient in front of a fixed beam.

“Introducing FIT within a major public healthcare institution demonstrates exactly what we envisioned for this platform: enabling health systems to integrate proton therapy into multidisciplinary cancer care while reducing the infrastructure barriers that have historically limited access,” said Tina Yu, Ph.D., President and CEO of Mevion Medical Systems.

The system achieves its compact footprint by integrating Mevion’s HYPERSCAN® pencil beam technology with Leo Cancer Care’s Marie® 360-degree upright patient positioning system and RaySearch Laboratories’ RayStation® treatment planning software. By fixing the proton beamline horizontally and rotating the patient in a specialized, upright diagnostic chair, the entire apparatus fits inside a standard 110-square-meter conventional linear accelerator (LINAC) vault. This reduces the vault volume by up to 70 percent and slashes total installation costs to an estimated $25 million to $35 million.

The clinical implications of upright radiotherapy extend beyond mere cost savings. Biomechanically, upright positioning offers distinct advantages, particularly for thoracic and lung oncology. Peer-reviewed studies demonstrate that seated patients exhibit increased functional residual lung volume and decreased diaphragmatic displacement during respiration. This limits the movement of respiratory tumors, allowing the proton beam to spare healthy lung and heart tissue with unprecedented precision. Furthermore, patient surveys indicate that upright positioning significantly improves comfort for dyspneic patients who struggle to breathe while lying flat, as well as postoperative breast cancer patients who experience pain when immobilized in a supine position.

The technology is rapidly gaining clinical validation. Just months ago, in June 2026, Stanford Medicine Cancer Center treated the world's first patient using the S250-FIT and Leo Cancer Care platform, proving the commercial and clinical viability of the upright architecture. Now, the technology is moving from Silicon Valley to the Bosphorus.

A Domestic Breakthrough for Public Health

For patients in Türkiye, the arrival of domestic proton therapy is a matter of urgent public health equity. Unlike conventional photon radiation, protons possess a unique physical property known as the Bragg peak. The beam can be programmed to deposit its maximum energy directly inside the tumor and then abruptly stop, resulting in zero exit dose.

This precision is indispensable for pediatric cancers—such as medulloblastomas and retinoblastomas—where collateral radiation can cause severe secondary malignancies, stunted skeletal growth, and cognitive impairment. It is equally critical for adults with complex skull-base tumors, ocular melanomas, or cancers wrapped around the spinal cord and optic nerve.

Historically, Turkish patients requiring this level of care have faced grueling medical evacuations. Under the Social Security Institution (SGK), tertiary medical boards have had to sponsor patients for treatment abroad, primarily funneling them to specialized centers in Germany, Switzerland, or the Czech Republic. These overseas treatments drain public health reserves, costing the state anywhere from €60,000 to €120,000 per patient—excluding the hidden costs of airfare, daily stipends, translation services, and the immense emotional toll of uprooting a sick child to a foreign country.

With an estimated 150 to 300 Turkish patients qualifying for proton therapy annually, the domestic installation at Çam ve Sakura City Hospital will conserve tens of millions of euros in foreign exchange outflows while democratizing access. Because the hospital operates under a Public-Private Partnership (PPP) model, the treatment will be integrated directly into Türkiye’s public healthcare infrastructure rather than being gated behind the exorbitant fees of exclusive private clinics.

“This investment reflects Rönesans’ long-term commitment to supporting Türkiye’s public healthcare system with advanced medical technologies and world-class infrastructure,” said Tuğrul Ertuğrul, CEO of Rönesans Healthcare Investment. “By introducing proton therapy at Çam ve Sakura City Hospital, under the leadership of the Ministry of Health and with the support of the Presidency, we are proud to contribute to expanding access to advanced cancer treatment for patients in Türkiye.”

Istanbul’s Bid for Regional Oncology Supremacy

The strategic placement of the MEVION S250-FIT at Başakşehir Çam ve Sakura City Hospital is no accident. Developed by Rönesans Healthcare Investment and Japan’s Sojitz Corporation, the hospital is an architectural marvel. Spanning over one million square meters and resting on 2,068 seismic isolators, it is one of the largest and most resilient medical complexes in Europe.

By embedding proton therapy within this mega-hospital, Türkiye is aggressively positioning itself to dominate the regional medical tourism market. Currently, there is a massive geographical void in advanced particle therapy. There are no active proton centers in the Balkans, Southeastern Europe, the South Caucasus, or Central Asia. Patients across a catchment area of over 300 million people—from Romania and Greece to Azerbaijan and Uzbekistan—have historically been forced to look to Western Europe or the United States for care.

Istanbul, already a global health tourism hub treating over 1.5 million foreign patients annually, is perfectly poised to capture this influx. Çam ve Sakura City Hospital is equipped with dedicated international patient lounges, three helipads, and direct metro connectivity, making it a frictionless destination for cross-border oncology care.

Local execution and long-term technical support will be spearheaded by Meditel Healthcare, a veteran medical technology distributor that has shaped the region’s radiation oncology landscape since 1984.

“This project is an important milestone for proton therapy in Türkiye,” noted Gökay Çelik, Senior Vice President and Board Member of Meditel Healthcare. “We have an opportunity not only to introduce an important new treatment capability at Çam ve Sakura City Hospital, but also to help establish Türkiye as an increasingly important regional center for advanced proton therapy.”

Installation of the system is slated to begin in November 2026, with the rigorous processes of beam tuning, physics commissioning, and end-to-end phantom testing to follow. If the timeline holds, the first patient will be treated before July 2027, marking the moment when the heavy, immovable legacy of traditional proton therapy is finally left behind, replaced by a smarter, leaner, and far more accessible future.